About Careers Internship MedBlogs Contact us
Medindia LOGIN REGISTER
Advertisement

Scientists Design Novel Compounds for Treating Muscular Dystrophy

by Kathy Jones on February 25, 2012 at 8:17 PM
Font : A-A+

 Scientists Design Novel Compounds for Treating Muscular Dystrophy

A series of small molecules that act against an RNA defect directly responsible for the most common form of adult-onset muscular dystrophy has been designed by Scripps Research scientists.

In two related studies, scientists from the Florida campus of The Scripps Research Institute found that these novel compounds significantly improve a number of biological defects associated with myotonic dystrophy type 1 in both cell culture and animal models.

Advertisement

"Our compounds attack the root cause of the disease and they improve defects in animal models," said Scripps Research Associate Professor Matthew Disney, PhD.

"This represents a significant advance in rational design of compounds targeting RNA. The work not only opens up potential therapies for this type of muscular dystrophy, but also paves the way for RNA-targeted therapeutics in general," Disney noted.
Advertisement

Myotonic dystrophy type 1 involves a type of RNA defect known as a "triplet repeat," a series of three nucleotides repeated more times than normal in an individual's genetic code.

In this case, the repetition of the cytosine-uracil-guanine (CUG) in RNA sequence leads to disease by binding to a particular protein, MBNL1, rendering it inactive. This results in a number of protein splicing abnormalities. Symptoms of this variable disease can include wasting of the muscles and other muscle problems, cataracts, heart defects, and hormone changes.

To find compounds that acted against the problematic RNA in the disease, Disney and his colleagues used information contained in an RNA motif-small molecule database that the group has been developing.

By querying the database against the secondary structure of the triplet repeat that causes myotonic dystrophy type 1, a lead compound targeting this RNA was quickly identified. The lead compounds were then custom-assembled to target the expanded repeat or further optimized using computational chemistry. In animal models, one of these compounds improved protein-splicing defects by more than 40 percent.

"There are limitless RNA targets involved in disease; the question is how to find small molecules that bind to them. We've answered that question by rationally designing these compounds that target this RNA. There's no reason that other bioactive small molecules targeting other RNAs couldn't be developed using a similar approach," Disney said.

The work has been published recently in online-before-print editions of Journal of the American Chemical Society and ACS Chemical Biology.

Source: ANI
Advertisement

Advertisement
News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
What's New on Medindia
COVID Toes
International Yoga Day 2022 - 'Yoga for Humanity'
Wearable Devices Are Now Transforming Depression, Multiple Sclerosis, and Epilepsy Management.
View all
News Archive
Date
Category
News Category

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

More News on:
Muscular Dystrophy 

Most Popular on Medindia

The Essence of Yoga Sinopril (2mg) (Lacidipine) Sanatogen Find a Hospital Selfie Addiction Calculator Nutam (400mg) (Piracetam) Hearing Loss Calculator Calculate Ideal Weight for Infants Turmeric Powder - Health Benefits, Uses & Side Effects Loram (2 mg) (Lorazepam)

Disclaimer - All information and content on this site are for information and educational purposes only. The information should not be used for either diagnosis or treatment or both for any health related problem or disease. Always seek the advice of a qualified physician for medical diagnosis and treatment. Full Disclaimer

© All Rights Reserved 1997 - 2022

This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use
open close
CONSULT A DOCTOR